“Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types. The agreements, of which financial terms were not disclosed, were signed through subsidiaries with Amgen Inc., Incyte Corporation, and Pfizer Inc.
“As part of the new collaborations, Merck will begin several clinical trials. In these phase I/II studies, MK-3475 will be explored in combination with axitinib in renal cell carcinoma, talimogene laherparepvec (T-VEC) in previously untreated advanced melanoma, the immunotherapy INCB24360 in previously treated metastatic recurrent non-small cell lung cancer (NSCLC), and PF-2566 in multiple cancer types. Separate from these collaborations, Merck announced that the safety and efficacy of MK-3475 monotherapy would be evaluated in a phase I “signal finding” study in 20 PD-L1-positive solid tumor types not previously studied.”